IP Library Granted Patent US 11,396,514
Granted Patent B2
US 11,396,514 · App. 16/474,339 · Granted Jul 26, 2022

Substituted guanidine compounds

Inventors: Ken-ichi Komori (Ube, JP); Akishi Ninomiya (Ube, JP); Shigeru Ushiyama (Ube, JP); Masaru Shinohara (Ube, JP); Koji Ito (Ube, JP); Tetsuo Kawaguchi (Ube, JP); Yasunori Tokunaga (Ube, JP); Hiroyoshi Kawada (Ube, JP); Haruka Yamada (Ube, JP); Yusuke Shiraishi (Ube, JP); Masahiro Kojima (Ube, JP); Masaaki Ito (Ube, JP); Tomio Kimura (Tokyo, JP)
C07D491/107C07D401/04C07D405/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,396,514
App. No.
16/474,339
Granted
Jul 26, 2022
Kind
B2
Abstract

The present invention provides a compound of general formula (I) (wherein X is as described in the present description and claims), or a pharmacologically acceptable salt thereof, and a pharmaceutical composition containing that compound.

Claims (26)

1. A compound of formula (I):

wherein,

X is a CR1R2,

R1 and R2, independently of each other, are a hydrogen atom, halogen atom, hydroxy group, optionally substituted C1-C6 alkyl group or optionally substituted C1-C6 alkoxy group, where the term “substituted” refers to being substituted with at least one substituent selected from the group consisting of a deuterium atom, halogen atom, hydroxy group and C1-C6 alkoxy group,

or a pharmacologically acceptable salt thereof.

2. The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein R1 is a hydrogen atom, halogen atom, hydroxy group, optionally substituted C1-C6 alkyl group or optionally substituted C1-C6 alkoxy group, and R2 is a hydrogen atom, halogen atom or C1-C3 alkyl group.

3. The compound according to claim 2 or a pharmacologically acceptable salt thereof, wherein R1 is a halogen atom, hydroxy group, C1-C6 alkoxy group or C1-C6 alkoxy group substituted with at least one deuterium atom.

4. A compound or a pharmacologically acceptable salt thereof, wherein the compound is:

2-fluoro-3-[5-fluoro-6-(3-methoxyazetidin-1-yl)pyridin-3-yl]benzyl carbamimidoylcarbamate, 2-fluoro-3-{5-fluoro-6-[3-(methoxy-d3)azetidin-1-yl]pyridin-3-yl}benzyl carbamimidoylcarbamate, 3-[6-(3-ethoxyazetidin-1-yl)-5-fluoropyridin-3-yl]-2-fluorobenzyl carbamimidoylcarbamate, 2-fluoro-3-{5-fluoro-6-[3-(2-fluoroethoxy)azetidin-1-yl]pyridin-3-yl}benzyl carbamimidoylcarbamate, 2-fluoro-3-[5-fluoro-6-(3-propoxyazetidin-1-yl)pyridin-3-yl]benzyl carbamimidoylcarbamate, 2-fluoro-3-[5-fluoro-6-(3-isopropoxyazetidin-1-yl)pyridin-3-yl]benzyl carbamimidoylcarbamate, 2-fluoro-3-(5-fluoro-6-{3-[(tetrahydropyran-2-yl)oxy]azetidin-1-yl}pyridin-3-yl)benzyl carbamimidoylcarbamate, 2-fluoro-3-[5-fluoro-6-(3-hydroxyazetidin-1-yl)pyridin-3-yl]benzyl carbamimidoylcarbamate, 3-[6-(azetidin-1-yl)-5-fluoropyridin-3-yl]-2-fluorobenzyl carbamimidoylcarbamate, 2-fluoro-3-[5-fluoro-6-(3-fluoroazetidin-1-yl)pyridin-3-yl]benzyl carbamimidoylcarbamate, 3-[6-(3,3-difluoroazetidin-1-yl)-5-fluoropyridin-3-yl]-2-fluoro-benzyl carbamimidoylcarbamate, 2-fluoro-3-[5-fluoro-6-(3-methylazetidin-1-yl)pyridin-3-yl]benzyl carbamimidoylcarbamate, 3-[6-(3,3-dimethylazetidin-1-yl)-5-fluoropyridin-3-yl]-2-fluorobenzyl carbamimidoylcarbamate, 2-fluoro-3-(5-fluoro-6-{3-methyl-3-[(tetrahydropyran-2-yl)oxy]azetidin-1-yl}pyridin-3-yl)benzyl carbamimidoylcarbamate, 2-fluoro-3-[5-fluoro-6-(3-hydroxy-3-methylazetidin-1-yl)pyridin-3-yl]benzyl carbamimidoylcarbamate or 2-fluoro-3-[5-fluoro-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-3-yl]benzyl carbamimidoylcarbamate.

5. The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein the compound is:

2-fluoro-3-[5-fluoro-6-(3-methoxyazetidin-1-yl)pyridin-3-yl]benzyl carbamimidoylcarbamate.

6. The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein the compound is:

2-fluoro-3-{5-fluoro-6-[3-(methoxy-d3)azetidin-1-yl]pyridin-3-yl}benzyl carbamimidoylcarbamate.

7. The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein the compound is:

2-fluoro-3-[5-fluoro-6-(3-hydroxyazetidin-1-yl)pyridin-3-yl]benzyl carbamimidoylcarbamate.

8. The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein the compound is:

2-fluoro-3-[5-fluoro-6-(3-fluoroazetidin-1-yl)pyridin-3-yl]benzyl carbamimidoylcarbamate.

9. The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein the compound is:

2-fluoro-3-[5-fluoro-6-(3-hydroxy-3-methylazetidin-1-yl)pyridin-3-yl]benzyl carbamimidoylcarbamate.

10. The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein the compound is:

2-fluoro-3-[5-fluoro-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)pyridin-3-yl]benzyl carbamimidoylcarbamate.

11. The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein the pharmacologically acceptable salt is a salt of an organic acid.

12. The compound according to claim 1 or a pharmacologically acceptable salt thereof, wherein the pharmacologically acceptable salt is a salt of a dicarboxylic acid.

13. A pharmaceutical composition comprising the compound according to claim 1 , or a pharmacologically acceptable salt thereof, and at least one type of pharmacologically acceptable additive.

14. The compound of claim 1 , wherein R1 and R2 are the same.

15. The compound of claim 1 , wherein R1 and R2 are different.

Assignments (2)
CHANGE OF NAME Recorded May 25, 2022
From: UBE INDUSTRIES, LTD.
To: UBE CORPORATION
Reel/Frame 060176/0536 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 9, 2019
From: KOMORI, KEN-ICHI; NINOMIYA, AKISHI; USHIYAMA, SHIGERU; SHINOHARA, MASARU; ITO, KOJI; KAWAGUCHI, TETSUO; TOKUNAGA, YASUNORI; KAWADA, HIROYOSHI; YAMADA, HARUKA; SHIRAISHI, YUSUKE; KOJIMA, MASAHIRO; ITO, MASAAKI; KIMURA, TOMIO
To: UBE INDUSTRIES, LTD.
Reel/Frame 050009/0445 →
Priority Claims (1)
JP JP2016-255567 · Dec 28, 2016 · national
Continuity (1)
Related Publication 20190337962A1 · Nov 7, 2019